GlaxoSmithKline
Jul 17, 2008
Genentech Needs More Profit Power
Genentech reported yesterday that its first-quarter overall revenue rose nearly 8%. Its top drugs, including cancer treatments Avastin and Rituxan, posted blowout double-digit sales growth.
Comments
Please note by clicking on "Post Comment" you acknowledge that you have read the Terms of Service and the comment you are posting is in compliance with such terms. Be polite. Inappropriate posts may be removed by the moderator. Send us your feedback.
| Topic | Updated | Last By | Comments |
|---|---|---|---|
| 'Hundreds' more claim thyroid drug side-effects | 7 hr | Jill Scott | 8 |
| Psychiatrist Accused of $2.8 Million Payola Fro... | Oct 7 | HumanSpirit | 3 |
| FDA Warns of Suicide Risk for Paxil (from May '06) | Oct 5 | Lis | 70 |
| Fluticasone now in generic, sort of (from Jun '06) | Oct 3 | Leigh | 56 |
| Pazopanib Shows Encouraging Activity In Several... | Sep 29 | catherine | 1 |
| GlaxoSmithKline buys Lovaza-maker Reliant for $... | Sep 21 | Yvonna | 1 |
| Family may sue Paxil over teen suicide | Sep 16 | frusciante | 1 |
Scorpio
Most Popular